+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030- Product Image
DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030- Product Image
Sale

DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6014421
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The DNA Vaccine Market grew from USD 263.93 million in 2023 to USD 302.54 million in 2024. It is expected to continue growing at a CAGR of 13.84%, reaching USD 654.23 million by 2030.

DNA vaccines represent a cutting-edge advancement in immunization, promising benefits like rapid development and stability over traditional vaccines. By introducing a small, circular DNA molecule encoding the antigen of the pathogen, DNA vaccines stimulate an immune response without the pathogen itself, conferring protection against diseases. Their necessity is driven by the need for effective and swift responses to emerging infectious diseases, particularly those with rapid mutation rates such as influenza or COVID-19. The application spans human healthcare, veterinary medicine, and agricultural biotechnology, with end-use extending to hospitals, clinics, research organizations, and biotech companies. Market growth is majorly fueled by rising investment in R&D and advancements in genetic engineering technologies. Additionally, the increasing prevalence of chronic and infectious diseases boosts the demand for efficient vaccines.

Key growth influencers include technological advancements, an increasing number of clinical trials, and supportive government initiatives towards vaccine development. However, opportunities lie in addressing the unmet needs of vaccine stability in developing regions, personalized medicine, and expanding applications to other viral and non-viral pathogens. The market faces limitations such as high costs associated with R&D, regulatory challenges, and public skepticism regarding genetic immunization, hindering products' widespread adoption. The requirement for cold chain infrastructure in distribution further challenges market expansion.

Innovative areas ripe for exploration include enhancing delivery mechanisms like electroporation and developing more efficient adjuvants to strengthen immune responses. Insightful exploitation of synergizing DNA vaccines with other therapeutic modalities, such as checkpoint inhibitors in cancer therapy, could broaden market applications. Biotech firms are urged to foster public-private partnerships, streamline regulatory processes, and invest in extensive education campaigns to address public hesitance. DNA vaccines' market nature is highly dynamic, rapid advancing due to competitive R&D ecosystems, making early adoption of emerging technologies crucial for companies aiming to establish a competitive edge.

Understanding Market Dynamics in the DNA Vaccine Market

The DNA Vaccine Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing need for rapid and scalable vaccine production methodologies
    • Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
    • Increasing collaboration between public and private sectors for vaccine development
    • Expansion of vaccination programs in developing regions boosting market growth
  • Market Restraints
    • Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
    • Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
  • Market Opportunities
    • Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
    • Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
    • Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
  • Market Challenges
    • Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
    • Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry

Exploring Porter’s Five Forces for the DNA Vaccine Market

Porter’s Five Forces framework further strengthens the insights of the DNA Vaccine Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the DNA Vaccine Market

External macro-environmental factors deeply influence the performance of the DNA Vaccine Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the DNA Vaccine Market

The DNA Vaccine Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the DNA Vaccine Market

The DNA Vaccine Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the DNA Vaccine Market

The DNA Vaccine Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the DNA Vaccine Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bioject Medical Technologies Inc., Emergent BioSolutions, ExcellGene SA, Genentech, Inc., GeneOne Life Science, Inc., GeoVax Labs, Inc., Immunomic Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, OncoSec Medical Incorporated, Profectus BioSciences, Inc., TechnoVax Inc., Vaccibody AS, Vaxess Technologies Inc., and Vical Incorporated.

Market Segmentation & Coverage

This research report categorizes the DNA Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Plasmid DNA Vaccine
    • Recombinant Protein Vaccine
    • Viral Vector Vaccine
  • Application
    • Allergy
    • Infectious Diseases
    • Oncology
  • End-User
    • Academic & Research Institutes
    • Contract Research Organizations
    • Pharmaceutical Companies
  • Delivery Method
    • Gene Gun
    • Jet Injector
    • Needle-Free Injection
      • Biojector
      • Electroporation
  • Technology
    • Electroporation Delivery
    • Gene Gun Delivery
    • Liposome-Mediated Delivery
  • Therapeutic Area
    • Allergy
    • Autoimmune Disorders
    • Cancer
    • Infectious Diseases
  • Route of Administration
    • Intradermal
    • Intramuscular
    • Intranasal
    • Subcutaneous
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing need for rapid and scalable vaccine production methodologies
5.1.1.2. Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
5.1.1.3. Increasing collaboration between public and private sectors for vaccine development
5.1.1.4. Expansion of vaccination programs in developing regions boosting market growth
5.1.2. Restraints
5.1.2.1. Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
5.1.2.2. Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
5.1.3. Opportunities
5.1.3.1. Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
5.1.3.2. Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
5.1.3.3. Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
5.1.4. Challenges
5.1.4.1. Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
5.1.4.2. Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. DNA Vaccine Market, by Type
6.1. Introduction
6.2. Plasmid DNA Vaccine
6.3. Recombinant Protein Vaccine
6.4. Viral Vector Vaccine
7. DNA Vaccine Market, by Application
7.1. Introduction
7.2. Allergy
7.3. Infectious Diseases
7.4. Oncology
8. DNA Vaccine Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Contract Research Organizations
8.4. Pharmaceutical Companies
9. DNA Vaccine Market, by Delivery Method
9.1. Introduction
9.2. Gene Gun
9.3. Jet Injector
9.4. Needle-Free Injection
9.4.1. Biojector
9.4.2. Electroporation
10. DNA Vaccine Market, by Technology
10.1. Introduction
10.2. Electroporation Delivery
10.3. Gene Gun Delivery
10.4. Liposome-Mediated Delivery
11. DNA Vaccine Market, by Therapeutic Area
11.1. Introduction
11.2. Allergy
11.3. Autoimmune Disorders
11.4. Cancer
11.5. Infectious Diseases
12. DNA Vaccine Market, by Route of Administration
12.1. Introduction
12.2. Intradermal
12.3. Intramuscular
12.4. Intranasal
12.5. Subcutaneous
13. Americas DNA Vaccine Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific DNA Vaccine Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa DNA Vaccine Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DNA VACCINE MARKET RESEARCH PROCESS
FIGURE 2. DNA VACCINE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 15. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 17. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 19. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DNA VACCINE MARKET DYNAMICS
TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY RECOMBINANT PROTEIN VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY JET INJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY BIOJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY LIPOSOME-MEDIATED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. CANADA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 69. CANADA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 70. CANADA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. CANADA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 72. CANADA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. MEXICO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 77. MEXICO DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 80. MEXICO DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. CHINA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. CHINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. CHINA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 111. CHINA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 112. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. CHINA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. CHINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. INDIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. INDIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. INDIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. INDIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 119. INDIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 120. INDIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. INDIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 122. INDIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. JAPAN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. JAPAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. JAPAN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. JAPAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 135. JAPAN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 136. JAPAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. JAPAN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 138. JAPAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. THAILAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. THAILAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. THAILAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. THAILAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 183. THAILAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 184. THAILAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. THAILAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 186. THAILAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 204. DENMARK DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. DENMARK DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. DENMARK DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 208. DENMARK DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 209. DENMARK DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. DENMARK DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 211. DENMARK DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. EGYPT DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 218. EGYPT DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. FINLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. FINLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 224. FINLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 225. FINLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 226. FINLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 227. FINLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. FRANCE DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. FRANCE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. FRANCE DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. FRANCE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 232. FRANCE DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 233. FRANCE DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. FRANCE DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 235. FRANCE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. GERMANY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. GERMANY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. GERMANY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. GERMANY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 240. GERMANY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 241. GERMANY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. GERMANY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 243. GERMANY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. ITALY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 253. ITALY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. ITALY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. ITALY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 256. ITALY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 257. ITALY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. ITALY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 259. ITALY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. NORWAY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. NORWAY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. NORWAY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 280. NORWAY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 281. NORWAY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. NORWAY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 283. NORWAY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. POLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 285. POLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. POLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 287. POLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 288. POLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 289. POLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. POLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 291. POLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. QATAR DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 293. QATAR DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. QATAR DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 295. QATAR DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 296. QATAR DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 297. QATAR DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. QATAR DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 299. QATAR DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. SPAIN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 325. SPAIN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. SPAIN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 327. SPAIN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 328. SPAIN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 329. SPAIN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 330. SPAIN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 331. SPAIN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 337. SWEDEN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 338. SWEDEN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 339. SWEDEN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 345. SWITZERLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 348. TURKEY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 349. TURKEY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 350. TURKEY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 351. TURKEY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 352. TURKEY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 353. TURKEY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 354. TURKEY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 355. TURKEY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 356. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 357. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 358. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 359. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 360. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 361. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 362. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 363. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 364. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 365. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 366. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 367. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 368. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 369. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 370. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 371. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 372. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 373. DNA VACCINE MARKET, FP

Companies Mentioned

The leading players in the DNA Vaccine Market, which are profiled in this report, include:
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bioject Medical Technologies Inc.
  • Emergent BioSolutions
  • ExcellGene SA
  • Genentech, Inc.
  • GeneOne Life Science, Inc.
  • GeoVax Labs, Inc.
  • Immunomic Therapeutics, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • OncoSec Medical Incorporated
  • Profectus BioSciences, Inc.
  • TechnoVax Inc.
  • Vaccibody AS
  • Vaxess Technologies Inc.
  • Vical Incorporated

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 302.54 Million
Forecasted Market Value ( USD ) by 2030 $ 654.23 Million
Compound Annual Growth Rate13.8%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Aquaculture Vaccines Market by Type, Product, Route of Administration, Application, End-User - Global Forecast 2025-2030 - Product Image

Aquaculture Vaccines Market by Type, Product, Route of Administration, Application, End-User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Travel Vaccines Market by Type, Disease - Global Forecast 2025-2030 - Product Image

Travel Vaccines Market by Type, Disease - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Influenza Market - Vaccines and Therapeutics - Product Image

Influenza Market - Vaccines and Therapeutics

  • Report
  • 387 Pages
  • Global
From
Vaccine Contract Manufacturing - Global Strategic Business Report - Product Image

Vaccine Contract Manufacturing - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Porcine Vaccines - Global Strategic Business Report - Product Image

Porcine Vaccines - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From

About the Market

DNA vaccines are a type of genomics-based vaccine that uses genetic material from a virus or bacteria to stimulate an immune response. They are created by introducing a gene that codes for a specific antigen into a plasmid, which is then inserted into a host cell. The host cell then produces the antigen, which is then used to stimulate an immune response. DNA vaccines are considered to be safer than traditional vaccines, as they do not contain any live virus or bacteria. Additionally, they can be produced more quickly and cheaply than traditional vaccines. DNA vaccines have been used to treat a variety of diseases, including influenza, malaria, and HIV. They have also been used to develop vaccines for cancer and other diseases. Recently, DNA vaccines have been used to develop vaccines for the prevention of infectious diseases, such as Zika virus and Ebola. Companies in the DNA Vaccines market include Moderna, Inovio Pharmaceuticals, Novavax, and Transgene. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.